Early activation of myogenesis in the somite depends on signals from surrounding tissues. Canonical β-catenin dependent Wnt signalling preferentially activates Myf5. We now show, in explant experiments with presomitic mesoderm, that the expression of another myogenic determination factor, MyoD, depends on non-canonical Wnt signalling, probably emanating from the dorsal ectoderm. Inhibitors of PKC block MyoD expression, indicating that the intracellular Wnt pathway depends on this kinase. In the absence of Myf5 and Mrf4, this activation is only minorily affected and we identify Pax3 as the transcriptional mediator responsible for MyoD expression. When embryos expressing a constitutively active form of Pax3, PAX3-FKHR, are used for these studies in the presence of PKC inhibitors, MyoD expression is not affected, suggesting that Wnt signalling acts on the transcriptional activity of Pax3.
Introduction
Skeletal myogenesis is initiated in the paraxial mesoderm in response to signalling molecules produced by neighbouring tissues, such as the neural tube, and the notochord or the dorsal ectoderm, leading to the activation of myogenic regulatory factor genes such as Myf5 and MyoD (Tajbakhsh et al., 1998) . These signalling molecules include members of the Wnts, Bmp and Shh families. Wnts constitute a large gene family, related to Drosophila wingless, and encoding secreted glycoproteins which are implicated in a multitude of developmental processes. Wnts bind to Frizzled (Fz) receptors on target cells to activate different signalling pathways, on the basis of which they can be divided into two main classes. Some Wnts, such as Wnt1, Wnt3a and Wnt8, activate the so-called canonical pathway, leading, through inactivation of glycogen synthase kinase (GSK-β3), to stabilization and subsequent nuclear translocation of β-catenin which then activates TCF/LEF1 (T-cell factor/ lymphocyte enhancer factor) transcription factors and induces Wnt-responsive genes (Eastman and Grosschedl, 1999; Filali et al., 2002; Pilon et al., 2006; Reya et al., 2003) . In contrast, other Wnts, such as Wnt5a, have been described to activate other signalling pathways in different cell systems, such as the planar cell polarity-like pathway and the Wnt/Ca2+ pathway, through a β-catenin-independent noncanonical intracellular cascade involving protein kinase C (PKC) and c-Jun NH2-terminal kinase (JNK) (Jin et al., 2005; Sheldahl et al., 1999) . Wnt7a and Wnt11, on the other hand have been shown to act both through a canonical and a non-canonical pathway (Adamska et al., 2004 (Adamska et al., , 2005 Kengaku et al., 1998; Pandur et al., 2002a; Tao et al., 2005) in different cell systems. It would appear that the same Wnt can signal through different signalling pathways and that Developmental Biology 304 (2007) 604 -614 www.elsevier.com/locate/ydbio complex cross-talk between these different pathways may regulate the cellular readout of Wnt signalling (Pandur et al., 2002b) . PKA may be another player in these complex intracellular signalling pathways leading to myogenesis. It has been demonstrated that adenyl cyclase signalling via PKA and its target transcription factor, CREB, are required for Wnt-directed myogenic gene expression (Chen et al., 2005) . Wnt proteins can also stimulate CREB-mediated transcription, providing evidence for a Wnt signalling pathway involving PKA and CREB. However it is not clear whether and how this PKA dependent Wnt signalling could affect specifically MyoD or Myf5 or both, and whether there is cross-talk between this pathway and the β-catenin pathway.
We previously showed that Wnt1 and Wnt3a, produced in the dorsal neural tube, adjacent to the site of epaxial myogenesis, preferentially activate Myf5 whereas Wnt7a and Wnt6, produced in the dorsal ectoderm, preferentially induce activation of MyoD (Cossu et al., 1996; Tajbakhsh et al., 1998) , which can occur in the absence of Myf5/Mrf4. Recently we showed direct activation of a Myf5 regulatory element that targets early epaxial myogenesis, by activated β-catenin (Borello et al., 2006) . Since Wnt7a may, in some contexts, act through a non-canonical pathway, we decided to investigate whether the Myf5 independent activation of MyoD, first observed during hypaxial myogenesis, was occurring in a β-catenin independent way.
By using a combination of genetic and pharmacological tools, we demonstrate here that in explants of pre-somitic mesoderm (PSM), MyoD expression can be activated in the absence of functional β-catenin and of Myf5, indicating that myogenesis can be induced through a PKC dependent, β-catenin independent, pathway. We also demonstrate that Pax3 is required in this pathway and that its transcriptional activity depends on PKC.
Materials and methods

Mouse lines
Generation and genotyping of the Pax3
LacZ/LacZ and Myf5 LoxP/LoxP have been described elsewhere (KassarDuchossoy et al., 2004; Relaix et al., 2003 Relaix et al., , 2004 β-catenin floxdel/floxed mice were obtained by intercrossing β-catenin floxdel/+ with β-catenin floxed/floxed mice (Brault et al., 2001; Lallemand et al., 1998) .
Organ and cell culture and infection
For most experiments, embryos ranging in age from 20 to 25 somites (E9.5 days) were isolated in PBS. The tissues were then digested with 0.25% pancreatin-0.1% trypsin for 5 min at 4°C. After the enzymatic digestion, the various tissues were mechanically separated according to the experimental scheme and then cultured in complete medium (see below). Unless otherwise indicated, presomitic mesoderm (PSM) refers to paraxial mesoderm immediately posterior to the most newly formed somite, alone with no associated structures. In some experiments dorsal ectoderm was left associated with the PSM and this is specified in the text.
All cultures were grown in RPMI medium (SIGMA) supplemented with 15% fetal calf serum (GIBCO), 300 mM β-mercaptoethanol and 50 mg/ml gentamycin. In experiments where co-culture with Wnt expressing cells was required, the tissue fragment were seeded onto a layer of 3T3 cells expressing Wnt1 or Wnt7a as previously described (Borello et al., 1999) .
3 h after plating, inhibitors were added to the culture, at the following concentrations: Calphostin C (1 μM), Bisindolylmaleimide I (500 nM), the JNK inhibitor SP600125 w(10 μM), rottlerin (5 μM), Go6976 (5 nM), (CALBIO-CHEM), KIC1-1 (Classical PKC Inhibitor), KIE1-1 (Epsilon PKC Inhibitor peptide), KIET1-1 (Eta PKC Inhibitor peptide), KIBI31-1 (BetaI PKC Inhibitor peptide), KIBII31-1 (BetaII PKC Inhibitor peptide), KIG31-1, (Gamma PKC Inhibitor peptide) (1 μM) (KAIPHARMA). Unless otherwise indicated, inhibitors were added every 24 h, the inhibitor peptides every 8 h, and the culture was carried out for a total of 60 h to allow the beginning of myogenic differentiation.
The CRE lentiviral vector (in pRRLsin.PPT.CMV.NTRiresGFPpre) was generated and prepared as described previously (Borello et al., 2006) . The final MOI was 5 × 10 7 PFU/ml. After 6 h culture, the explants were infected with a MOI of 100 in RPMI/15%FCS overnight. The following day the medium was changed. The explants were cultured for a total of 3 days. To test for the correct excision of the floxed β-catenin, PCR was performed on genomic DNA from the explant at different times, with the following primers:
RM41: AAG GTA GAG TGA TGA AAG TTG TT; RM42: CAC CAT GTC CTC TGT CTA TCC; RM43: TAC ACT ATT GAA TCA CAG GGA CTT.
In addition RT-PCR was performed on RNA extracted from the explants at different times using the following primers:
Cre Fw: GACCAAGTGACAGCAATGCTGTTTCA; Cre rev: CACCAGCTTGCATGATCTCCGGTATT; β-catenin Fw: GTGCAATTCCTGAGCTGACA; β-catenin rev: CTTAAAGATGGCCAGCAAGC-3′; GAPDH Fw: TGAAGGTCGGAGTCAACGGATTTGGT; GAPDH Rev: CATGTGGGCCATGAGGTCCACCAC.
At the times indicated, cultures were fixed and immunofluorescence was performed using different antibodies.
Immunofluorescence
Immunofluorescence on cultured explants was carried out as described (Brunelli et al., 2004) using the following antibodies and dilutions: goat polyclonal anti β-galactosidase (Biogenesis) antibody (1:350); MF20 antisarcomeric myosin monoclonal antibody (DHSB) (1:4); mouse monoclonal anti-MyoD antibody (DAKO) (1:200); rabbit polyclonal anti Myf5 antibody (Santa Cruz) (1:300); rabbit polyclonal anti-sarcomeric myosin antibody (Cusella-De Angelis et al., 1994) (1:500); anti-GFP rabbit polyclonal antibody (Molecular Probes)(1:300); anti-GFP monoclonal antibody (Molecular Probes) (1:200). Primary antibodies were detected by appropriate secondary antibodies (Molecular Probes), conjugated with either Alexa 594, or Alex 498, for fluorescence detection.
Protein extraction and Western analysis
Embryos or cultured explants were washed in PBS and solubilised in the following lysis buffer: 20 mM MOPS, pH 7. 2 mM EGTA, 5 mM EDTA, 30 mM sodium fluoride, 40 mM β-glycerophosphate, pH 7.2, 20 mM sodium pyrophosphate, 1 mM sodium orthovanadate, 1 mM phenylmethylsulfonylfluoride, 3 mM benzamidine, 5 μM pepstatin A, 10 μM leupeptin, 0.5% Nonidet P-40. The protein extracts (1 mg/ml) were boiled for 4 min at 100°C in SDS-PAGE Sample Buffer (31.25 mM Tris-HCl (pH 6.8), 1% SDS (w/v), 12.5% glycerol (v/v), 0.02% bromophenol blue (w/v), and 1.25% β-mercaptoethanol). Alternatively PSM was solubilised in the same lysis buffer minus sodium orthovanadate and with 1 mM EDTA, then incubated for 60 min at 37°C with 20 units of Calf Intestinal Alkaline Phosphatase (CIP), then boiled in the sample buffer.
Samples were either shipped to KINEXUS (Canada) to be analyzed by KINETWORKS™ PHOSPHO-SITE SCREEN 4.1, or loaded onto 10% sodium dodecyl sulfate-polyacrylamide gels for Western analysis. After electrophoresis, polypeptides were electrophoretically transferred to nitro-cellulose filters (Schleicher and Schuell, Dassel, Germany) and antigens revealed by the following primary monoclonal antibodies: mouse anti-PKCα, PKCβ, PKCδ, PKCε, PKCη, PKCγ, PKCλ (BD-Transduction Laboratories)(Lexington, KY, USA), mouse anti-PAX3 mAb (Hybridoma Bank), anti-Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mAb from Biogenesis (Poole, England). Primary antibodies were detected by chemiluminescence with appropriate horseradish peroxidase-conjugated secondary antibodies (Biorad, Hercules, CA, USA).
Image acquisition and manipulation
Images in fluorescence were taken on the Nikon microscope Eclipse E600 (lenses Plan Fuor: 4×/013, 10×/0.33, 20×/0.50, 40×/0.75). All images have been acquired using the NIKON digital camera DXM1200, and the acquisition software NIKON ACT-1. Images were than assembled in panels using Adobe Photoshop 7.0.
Statistical analysis
The results are expressed as means ± S.E.M.; n represents the number of individual experiments. Statistical analysis was carried out using the ANOVA one way analysis of variance. Asterisks in the figure panels refer to statistical probabilities vs. untreated controls. Statistical probability values (P) of less than 0.05 were considered significant.
Results
MyoD activation can occur independently of β-catenin
We investigated the requirement of β-catenin for MyoD or Myf5 expression, by analyzing this in a β-catenin null genetic background. We infected presomitic mesoderm explants (PSM), dissected from embryonic day (E) 9.5 β-catenin (Figs. 1D, I )) as described previously (Borello et al., 2006) . Under these conditions MyoD expression is also reduced (Figs. 1C, G, I ). On the other hand, MyoD expression, induced in the presence of dorsal ectoderm, was not affected (Figs. 1A, E, I). [Suppl. Fig. 1 provides images of the DAPI staining corresponding to panels A-H in Fig. 1 ]. These data suggest that β-catenin signalling plays an important role in neural tube mediated expression of these myogenic determination factors in the PSM, but not in that mediated by dorsal ectoderm, indicating that the latter depends on a β-catenin independent pathway.
PKC inhibitors abrogate dorsal ectoderm or Wnt7a dependent myogenesis in the PSM
Two non-canonical Wnt pathways have been described, namely the Wnt/Ca(2+) pathway, which goes through protein kinase C (PKC), and the Wnt/PCP pathway involving Rho/Rac small GTPases and Jun N-terminal kinase (JNK) classes of transduction molecules. We examined whether the expression of MyoD, which depends on dorsal ectoderm and can be induced by Wnt7a (Tajbakhsh et al., 1998) , requires the presence of functional PKC or JNK activities.
PSM was dissected free of dorsal ectoderm or neural tube, from E9.5 embryos and cocultured on a layer of 3T3 cells expressing either Wnt7a ( Figs . The explants were left to differentiate for 3 days (drugs were added 3 h after plating and then every 24 h), before examination of Myf5 or MyoD expression. As previously described (Tajbakhsh et al., 1998) These results indicate that dorsal ectoderm (and Wnt7a) signals mainly through activation of the PKC pathway. Myf5 is not strongly activated by this signal but its expression may account for the residual MyoD expression in the presence of PKC inhibitors, since MyoD can be directly activated by Myf5 (Tajbakhsh et al., 1997) .
We therefore decided to perform similar experiments in Myf5 mutant mice in which early myogenesis is driven only by MyoD. We dissected presomitic mesoderm (PSM), including dorsal ectoderm or neural tube from Myf5 nlacZ/nlacZ embryos, which are null mutant for both Myf5 and Mrf4, or the sibling Myf5 nlacZ/+ , or Myf5
LoxP/LoxP embryos, in which Mrf4 is still present (KassarDuchossoy et al., 2004). The explant cultures were left to In addition in these experiment we were able to test the expression of β-Galactosidase (β-Gal) as a readout of Myf5 activation (Figs. 3B, D, F , H, L, N, P, Q). This confirms that while the neural tube strongly activated β-Gal expression in PSM explants (Figs. 3F, N, Q) , fewer βGal expressing cells were present in dorsal ectoderm induced explants (Figs. 3B, J, Q) .
This expression was not affected by the presence of PKC inhibitors (Figs. 3D , H, L, P Q), suggesting that dorsal ectoderm signalling leading to Myf5 activation is not PKC dependent. We observed a similar reduction in MyoD expressing cells in explants from Myf5
LoxP/LoxP embryos when PKC, but not JNK signalling, was inhibited, in all sets of experiments (Suppl. Fig.  3W and not shown). This shows that Mrf4, is not implicated in MyoD regulation by the dorsal ectoderm signal. These results confirm that MyoD expression, induced by the dorsal ectoderm, is compromised in the absence of activated PKC and that this effect is even more pronounced in the absence of Myf5. 
Several PKC isoforms are expressed in presomitic mesoderm and are involved in MyoD expression
The tissue distribution of different PKC isoforms has only been partially documented during development (Bogatkevich et al., 2005; Hamplova et al., 2005; Oehrlein et al., 1998; Pauken and Capco, 2000; Redling et al., 2004; Wilda et al., 2001 ) and we therefore explored whether any particular isoform was specifically expressed in the PSM, where it could play a role in the non-canonical pathway leading to MyoD expression.
We initially assessed the expression of various PKC isoforms in extracts of the PSM, compared to the total embryo, at E9.5 by Western blot analysis. As shown in Fig. 4A , PSM expresses PKCα, β, η, γ, δ, ε, λ at high to detectable levels, the majority at similar levels to those in the total embryo, except for α and δ, which appear to be enriched in the PSM. We took advantage of several newly identified peptides that inhibit specific PKC isoforms (Disatnik et al., 2002) to investigate which of the PSM isoforms were mainly responsible for MyoD expression. We tested inhibitors of PKCβI, βII, γ, ε, and η on the differentiation of Myf5
LoxP/LoxP PSM explants. We also tested two drugs that show a certain degree of selectivity for PKCα (Go6976) and PKCδ (rottlerin) (Renault-Mihara et al., 2006) . While inhibition of PKCβII, γ or ε did not have significant effects on MyoD expression, we observed that this is reduced in the presence of selective inhibitors of PKCβI and η and to some extent by inhibitors that preferentially effect PKCδ and PKCδ (Fig. 4B) . This suggests that, of the isoforms tested, βI, η, and also possibly α and δ, may be involved in the transduction of non-canonical Wnt signalling, leading to MyoD expression.
Inhibition of PKC activity in the PSM alters the phosphorylation state of many kinases playing a role in different signal transduction pathways While the involvement of PKC and, in some instances, the final transcriptional target of the non-canonical Wnt pathway has been described in many systems (Jin et al., 2005; Koyanagi et al., 2005; Pandur et al., 2002a) , in the case of somitic myogenesis it is not known which are the substrates of PKC phosphorylation and how this signal is transduced.
We thus performed a differential phosphorylation profile analysis on protein extracts from explants of PSM and dorsal ectoderm, grown in the presence or absence of PKC inhibitor for 24 h. The analysis was carried out by the company KINEXUS using a panel of antibodies specific for phosphosites (Kinetworks™KPSS-4.1-Phospho-Site) (Fig. 5A, Table 1 ).
The inhibition of PKC activity in the PSM leads to the modification of the phosphorylation status of many different transduction molecules (Figs. 5A-B) . Of particular interest is the decreased phosphorylation of GSK3β, suggesting the existence of a cross-talk with the β-catenin dependent pathway, and of p38a MAPK and MKK6, known to be involved in the regulation of myotome development (De Angelis et al., 2005) . Increased phosphorylation was seen for ERK1, ERK2, PKCδ and Rb, but the significance of this remains to be investigated.
Pax3 transcriptional activity, but not Pax3 expression, is abrogated by PKC inhibitors, and is necessary to initiate MyoD dependent myogenesis
Pax3 is another key regulator of myogenesis. In the absence of both Myf5 and Mrf4, MyoD can still be activated. However the combined mutation in mouse embryos of Myf5, Mrf4 and Pax3 results in the absence of MyoD activation and the loss of all skeletal muscles in the trunk and limbs (KassarDuchossoy et al., 2004; Tajbakhsh et al., 1997) . It is, however, still unknown how Pax3 influences MyoD activation. We therefore decided to investigate whether Pax3 was involved in the Wnt7A/PKC pathway of MyoD expression. PSM explants from Pax3 GFP/+ embryos were left to differentiate with dorsal ectoderm, in the presence or absence of PKC inhibitors (Figs. 6A-B and Suppl. Figs. 3A-B) . As shown previously, we observed a reduction of MyoD expression and myogenesis in the presence of PKC inhibitors (Figs. 6B-C and Suppl. LoxP/LoxP embryos differentiated in the presence of the different isoform-specific inhibitors. Independent experiment (n = 8) were performed in triplicate and averaged. Single cross, single, double and triple asterisks represent P < 0.05, P < 0.03, P < 0.01 and P < 0.001 vs. control (C). Bars represent the S.E.M. C, not treated control; KI, Kaipharma, classical general PKC inhibitor (1 μM); Bis, Bisindolylmaleimide I (0.5 μM); Rot, rottlerin PKCδ inhibitor (5 μm), Go, Go6796, PKCα inhibitor (5 nM), PKCβI, peptide inhibitor of PKCβI; PKCβII, peptide inhibitor of PKCβII; PKCγ, peptide inhibitor of PKCγ; PKCε, peptide inhibitor of PKCε; PKC η, peptide inhibitor of PKC η, (all at 1 μM); all, combination of available PKC inhibitors. detectable in treated explants, although the level appears slightly lower. This suggested that in the absence of activated PKC, the Pax3 protein is unable to activate MyoD.
In order to test the transcriptional activity of Pax3 in this situation, we performed the same experiment on explants derived from P34 transgenic embryos, that express the reporter gene nlacZ driven by a Pax3 responsive element (Relaix et al., 2004) . In these mice the activity of the reporter depends on Pax3 transcriptional activity. We observed a drastic reduction in nlacZ expression, measured as expression levels of β-galactosidase, in explants grown in the presence of PKC inhibitors . Since Pax3 expression is not affected by these inhibitors, we conclude that the transcriptional activity of Pax3 requires PKC activity.
A constitutively active form of Pax3, PAX3-FKHR, overcomes the PKC requirement for MyoD expression PAX3-FKHR arises in humans as a result of a chromosomal translocation, t(2;13), which leads to the fusion of the potent Cterminal transcriptional activation domain of FKHR (FOX01A) to the N-terminal region of PAX3, which includes the intact paired-box and homeobox DNA-binding elements. PAX3-FKHR is a potent gain-of-function mutation and is able to rescue the Pax3 mutant phenotype (Relaix et al., 2003) . We decided to test whether this activated form of Pax3 was still dependent on PKC activity, by examining MyoD expression in explants of PSM and dorsal ectoderm from Pax3 PAX3-FKHR-IRESnlacZ/+ embryos, in the presence or absence of PKC inhibitors.
Explants from embryos expressing PAX3-FKHR are able to express MyoD and differentiate in the presence of PKC inhibitors . This therefore demonstrates that expression of MyoD at this stage depends on Pax3 transcriptional activity, since PKC inhibition is rescued by PAX3-FKHR. Pax3 contains several putative consensus sites for Ser/Thr phosphorylation, amongst which there are 8 sites for PKC, which are conserved in different species (mouse, human, chicken, xenopus). Pax3 mobility shift on SDS-PAGE gels is nevertheless not affected when PKC is inhibited by different inhibitors, but it is when the protein extract is treated with alkaline phosphatase, indicating that if phosphorylation of Pax3 is at stake, only a few phosphosites are affected by PKC (Fig. 6J ).
Discussion
PKC, but not β-catenin, is required for MyoD expression at the onset of myogenesis Early myogenesis can be triggered by two principal cascades, initiated by either the axial structures (neural tube and notochord) or the dorsal ectoderm via signalling molecule such as the wnts (Wnt1, Wnt3a and Wnt4 or Wnt6 and Wnt7A respectively) leading to the expression of Myf5 or MyoD in the Table 1 for the bands position) in PSM explants from E9.5 embryos co-cultured with dorsal ectoderm, treated (lower gel) or untreated (upper gel) with Bisindolylmaleimide I (0.5 μN) for 24 h, using antibodies for specific phosphosites. (B) Histogram showing the relative increase or decrease in phosphorylation of the phosphoproteins in Bisindolylmaleimide I (Bis) treated explants as a percentage of control explants. Only phosphoproteins that gave a positive signal, showing a difference higher than 5% between treated and control explants are reported here. mouse embryo (see Cossu et al., 1996; Tajbakhsh et al., 1998) . In the case of Myf5, we recently showed that its epaxial activation is due to a cooperative interaction between the Wnt/ β-catenin and the Shh/Gli pathways (Borello et al., 2006) . However it remains unknown whether Wnts activate MyoD through a canonical or a non-canonical pathway. We show here that Wnt-dependent expression of MyoD can occur independently of β-catenin but not of PKC signalling, therefore demonstrating the implication of a non-canonical Wnt pathway.
The non-canonical Wnt pathway has been described to regulate many developmental and differentiation processes (Kohn and Moon, 2005; Medina et al., 2000) . In particular, a PKC dependent non-canonical Wnt pathway has been associated with cardiomyogenesis both during Xenopus development and more recently in the differentiation of human circulating progenitor cells (Koyanagi et al., 2005; Pandur et al., 2002a) . Similarly to our findings, inhibition of PKC activity blocked cardiomyocyte differentiation. An involvement of PKC in skeletal myogenesis has been demonstrated, at least in cultured myoblasts and in the cell line C2C12. In contrast to our results, down-regulation of PKC appeared to be necessary to allow differentiation and myoblast fusion (Goel and Dey, 2002a,b) . However in these experiments PKC appeared not to mediate Wnt signalling, but probably an insulin or integrin signalling pathway.
PKC and PKA in the activation of myogenesis
Another kind of non-canonical pathway has been recently described in muscle progenitor cells in the PSM (Chen et al., 2005) . Wnt1 and Wnt7a potently induce transcription from a cyclic AMP-responsive element (CRE) promoter. By testing a barrage of inhibitors and dominant-negative mutants, evidence is presented that noncanonical Wnt signalling -specifically the adenylate cyclase (AC) cascade -activates CREB-mediated transcription and this process is physiologically relevant for Wnt-induced myogenesis. Increasing AC activity (or elevating cAMP levels) specifically enhanced expression of MyoD and Myf5 induced by Wnt1, whereas blocking AC or PKA activity inhibited both Wnt1-and Wnt7a-mediated myogenesis. Although these data show that AC activity affects both Myf5 and MyoD, they do not clarify whether either gene may be a direct target of CREB activity since the experiments were performed in wild type embryos with both MyoD and Myf5 present at the same time. Likewise, it is not obvious whether PKA dependent myogenesis occurs independently of the canonical pathway. Even if it appears that dominant negative CREB does not affect targets of the canonical pathway (Buttitta et al., 2003) , other data suggest that PKA, by directly phosphorylating β-catenin, inhibits its ubiquitination, therefore allowing its accumulation and activating the canonical Wnt signalling cascade (Hino et al., 2005) .
PKC intracellular pathways in myogenesis
How does PKC affect early myogenesis? The data presented here suggest that several molecules may mediate PKC activity. Some indications come from the analysis of the phosphorylation profile of a panel of phosphoproteins in the presence or absence of PKC activity. We observed that inhibition of PKC activity leads to a strong modification of the phosphorylation state of many proteins involved in important signal transduction pathways. In particular when PKC is inactive, phosphorylation of MKK6 and p38MAPK are strongly reduced. p38 MAPK signalling has been implicated in myogenesis with varying reports of its effects on Myf5 or MyoD expression (De Angelis et al., 2005; Keren et al., 2005; Penn et al., 2004; Wu et al., 2000) .
Inhibition of PKC led to a reduction of GSK3β phosphorylation. Cross-talk between the canonical and non-canonical Wnt pathways has been described, probably because they share common components such as Dsh (Kuhl, 2002; Kuhl et al., 2001) or GSK3β, already identified as a PKC substrate (De Servi et al., 2005; Oriente et al., 2001) . It is possible that during myogenesis cross-talk exists between the Wnt/PKC pathway and the Wnt/β-catenin pathway as suggested by the effect of PKC inhibitors on GSK3β phosphorylation, although in our PKC inhibition experiments we do not observe detectable effects on the low level of Myf5 expression in dorsal ectoderm induced myogenesis.
Pax3 transcriptional activation requires PKC
Another important player in early myogenic induction is Pax3. Analysis of mutant mice have shown that in the absence of the myogenic regulatory factors Myf5 and Mrf4, Pax3 is required for MyoD activation and the entry of cells into the skeletal muscle programme (Kassar-Duchossoy et al., 2004; Tajbakhsh et al., 1997) . Wnt signalling from the neural tube, acting through the β-catenin dependent pathway, leads to the early activation of myogenic regulatory genes, notably Myf5, which is a direct target of TCF/β-catenin (Borello et al., 2006) , in the epaxial dermomyotome of the somite. In the epaxial domain, the early expression of MyoD depends on Myf5/Mrf4 (Kassar-Duchossoy et al., 2004; Tajbakhsh et al., 1997) . Myf5 and Mrf4 are also transcribed in the hypaxial dermomyotome, where Pax3 is also strongly expressed. In this domain, MyoD expression initially depends on Myf5/Mrf4 but this is also transitory and indeed in the explant experiments reported here only a small additional effect was observed using Myf5/Mrf4 mutant embryos.
Wnt signalling from the dorsal ectoderm is probably most important for myogenesis in this hypaxial context, and also potentially for the Pax3/Pax7 positive progenitor cells derived from the central region of the dermomyotome of the mouse embryo (Relaix et al., 2005) . In the Myf5/Mrf4 double mutant, there is a minor delay in early MyoD activation in the hypaxial domain (Tajbakhsh et al., 1997) . The results reported here demonstrate that non-canonical Wnt signalling regulates MyoD expression in a Pax3-dependent manner, since in the presence of this transcription factor, MyoD expression is downregulated by PKC inhibitors, whereas in the presence of PAX3-FKHR it is not. Furthermore this observation provides insight into the way PKC affects Pax3 activity. Pax3 itself is a poor transcriptional activator and probably requires a co-activator or modifications in order to act efficiently (Relaix et al., 2003) . PAX3-FKHR, which has the strong activation domain of FKHR circumvents this requirement. We identify several potential phosphorylation sites for PKC in the Pax3 protein, which are conserved in other species. No detectable change in size is seen for Pax3, on the basis of electrophoretic mobility, in the presence of PKC inhibitors, however this may reflect the large number of phosphorylated residues, since a size change is detected on electrophoresis only after global dephosphorylation. Alternatively, or in addition, co-activator phosphorylation may be involved; we are currently looking for Pax3 interacting proteins in the myogenic context. We favour this explanation since Pax3 can also activate Myf5, probably through a different PKCindependent co-activator . Wnt signaling has been implicated in the maintenance of Pax3 expression in pre-somitic mesoderm (Fan et al., 1997) . Canonical Wnts such as Wnt1 derived from the neural tube have more effect than dorsal ectoderm derived Wnts such as Wnt6 although both signalling pathways act on Pax3. This represents a further level of regulation, in addition to that exerted by PKC dependent Wnt signalling from the dorsal ectoderm on Pax3 activity. Indeed the latter may affect Pax3 transcription through an autoregulatory feedback loop. In Pax3 nlacZ/nlacZ mice we continue to see β-galactosidase positive cells (Relaix et al., 2004) , indicating that Pax3 is not essential for at least some level of Pax3 transcription. Indeed in the presence of PKC inhibitors, Pax3 is still present, although slightly reduced.
In conclusion, we have provided new insights into the complex regulatory network that drives the early phases of embryonic myogenesis. We demonstrate that MyoD expression can occur in the absence of an active Wnt/β-catenin pathway, through a Wnt/PKC non-canonical pathway. We show that expression of MyoD is mainly Pax3 dependent and that Pax3 transcriptional activity is modulated by PKC, directly or indirectly by phosphorylation of the factor itself or putative co-factors. In addition we provide some insight into how activation of PKC by Wnt may act on the signal transduction of other signalling pathways, including the Wnt/β-catenin canonical pathway.
